

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide of Formula I consisting of all [D]-amino acids, or a retro-isomer of a peptide of Formula I consisting of all [D]-amino acids; wherein said peptide of Formula I is selected from the group consisting of:

<u>Lys-Ile-Val-Phe-Phe-Ala</u>	<u>(SEQ ID NO:1);</u>
<u>Lys-Lys-Leu-Val-Phe-Phe-Ala</u>	<u>(SEQ ID NO:2);</u>
<u>Lys-Phe-Val-Phe-Phe-Ala</u>	<u>(SEQ ID NO:4);</u>
<u>Lys-Ala-Val-Phe-Phe-Ala</u>	<u>(SEQ ID NO:7);</u>
<u>Lys-Val-Val-Phe-Phe-Ala</u>	<u>(SEQ ID NO:9);</u>
<u>Lys-Ile-Val-Phe-Phe-Ala-NH₂</u>	<u>(SEQ ID NO:10);</u>
<u>Lys-Phe-Val-Phe-Phe-Ala-NH₂</u>	<u>(SEQ ID NO:12);</u>
<u>Lys-Ala-Val-Phe-Phe-Ala-NH₂</u>	<u>(SEQ ID NO:15);</u>
<u>Lys-Val-Val-Phe-Phe-Ala-NH₂</u>	<u>(SEQ ID NO:17);</u>
<u>Lys-Leu-Val-Phe-Phe-Ala-Gln</u>	<u>(SEQ ID NO:18); and</u>
<u>Lys-Leu-Val-Phe-Phe-Ala-Gln-NH₂</u>	<u>(SEQ ID NO:19).</u>

~~Xaa₁-Xaa₂-Xaa₃-Xaa₄~~ (Formula I)

wherein,

~~Xaa₁ is selected from the group consisting of Lys and Xaa₅-Lys;~~

~~Xaa₅ is selected from the group consisting of Lys, His-Gln, His-His-Gln,~~

~~Val-His-His-Gln, Glu-Val-His-His-Gln, Asp-Asp-Asp, and Gln;~~

~~Xaa₂ is any amino acid;~~

~~Xaa₃ is Val; and~~

~~Xaa₄ is selected from the group consisting of Phe, Phe-NH₂, Phe-Phe, Phe-Phe-NH₂,~~

~~Phe-Phe-Ala, Phe-Phe-Ala-NH₂, Phe-Phe-Ala-Gln, and Phe-Phe-Ala-Gln-NH₂.~~

2-7. (Canceled).

8. (Currently Amended) ~~The antifibrillogenic agent of claim 1,~~ An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide consisting of all [D]-amino acids, or a retro-isomer of a peptide consisting of all [D]-amino acids, wherein the said peptide of Formula I is a peptide of SEQ ID NO:2.

9-19. (Canceled).

20. (Currently Amended) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of a peptide of ~~Formula I as defined in claim 1~~ or a retro-isomer thereof, and a pharmaceutically acceptable carrier.

21. (Previously Presented) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent as defined in claim 1, and a pharmaceutically acceptable carrier.

22-31. (Canceled).

32. (Previously Presented) A composition for inhibiting amyloidosis and/or for cytoprotection, which comprises a therapeutically effective amount of a peptide as defined in claim 1 or a retro-isomer thereof, and a pharmaceutically acceptable carrier.

33-38. (Canceled).

39. (Previously Presented) The composition of claim 20, wherein said amyloidosis disorder is Alzheimer's disease.

40. (Previously Presented) The composition of claim 21, wherein said amyloidosis disorder is Alzheimer's disease.

41. (Currently Amended) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises a peptide selected from the group consisting of:

Lys-Ile-Val-Phe-Phe-Ala	(SEQ ID NO:1);
Lys-Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:2);
Lys-Leu-Val-Phe-Phe-Ala	(SEQ ID NO:3);
Lys-Phe-Val-Phe-Phe-Ala	(SEQ ID NO:4);
Ala-Phe-Phe-Val-Leu-Lys	(SEQ ID NO:5);
Lys-Leu-Val-Phe	(SEQ ID NO:6);
Lys-Ala-Val-Phe-Phe-Ala	(SEQ ID NO:7);
Lys-Leu-Val-Phe-Phe	(SEQ ID NO:8);
Lys-Val-Val-Phe-Phe-Ala	(SEQ ID NO:9);
Lys-Ile-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:10);
Lys-Leu-Val-Phe-Phe-Ala-NH₂	(SEQ ID NO:11);
Lys-Phe-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:12);
Ala-Phe-Phe-Val-Leu-Lys-NH₂	(SEQ ID NO:13);
Lys-Leu-Val-Phe-NH₂	(SEQ ID NO:14);
Lys-Ala-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:15);
Lys-Leu-Val-Phe-Phe-NH₂	(SEQ ID NO:16);
Lys-Val-Val-Phe-Phe-Ala-NH ₂	(SEQ ID NO:17);
Lys-Leu-Val-Phe-Phe-Ala-Gln	(SEQ ID NO:18); <u>and</u>
Lys-Leu-Val-Phe-Phe-Ala-Gln-NH ₂	(SEQ ID NO:19);
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-NH₂	(SEQ ID NO:20);
His-His-Gln-Lys	(SEQ ID NO:23); <u>and</u>
Gln-Lys-Leu-Val-Phe-Phe-NH₂	(SEQ ID NO:24);

wherein said amino acid sequence consists of all [D]-amino acids.

42. (Previously Presented) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the sequence of SEQ ID NO:2, wherein said amino acid sequence consists of all [D]-amino acids.

43. (New) A composition for the treatment of amyloidosis disorders in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent comprising the amino acid sequence of SEQ ID NO:2 wherein said sequence consists of all [D]-amino acids, and a pharmaceutically acceptable carrier.

44. (New) A composition for the treatment of Alzheimer's disease in a patient, which comprises a therapeutically effective amount of an antifibrillogenic agent comprising the amino acid sequence of SEQ ID NO:2 wherein said sequence consists of all [D]-amino acids, and a pharmaceutically acceptable carrier.

45. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:1, wherein said sequence consists of all [D]-amino acids.

46. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:4, wherein said sequence consists of all [D]-amino acids.

47. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:7, wherein said sequence consists of all [D]-amino acids.

48. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:9, wherein said sequence consists of all [D]-amino acids.

49. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:10, wherein said sequence consists of all [D]-amino acids.

50. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:12, wherein said sequence consists of all [D]-amino acids.

51. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:15, wherein said sequence consists of all [D]-amino acids.

52. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:17, wherein said sequence consists of all [D]-amino acids.

53. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:18, wherein said sequence consists of all [D]-amino acids.

54. (New) An antifibrillogenic agent for inhibiting amyloidosis and/or for cytoprotection, which comprises the amino acid sequence of SEQ ID NO:19, wherein said sequence consists of all [D]-amino acids.